Estados financieros detallados de Prime Medicine, Inc. (PRME): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Prime Medicine, Inc. registró ingresos de $4.6M en el último ejercicio fiscal, con un CAGR de 5 años del -2.3%.
Márgenes de los últimos 12 meses: margen bruto -10.3%, margen operativo -48.2%, margen neto -46.1%.
Al precio actual de $3.00, PRME presenta beneficios negativos (P/E no significativo) y un ROE del -188.27%. La capitalización bursátil es de $542M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | $5.2M | 0 | 0 | 0 | $3.0M | $4.6M |
| Coste de Ventas | $2.8M | $3.0M | 0 | 0 | 0 | 0 | $7.3M |
| Beneficio Bruto | -$2.8M | $2.2M | 0 | 0 | 0 | $3.0M | -$2.7M |
| I+D | $920000 | $3.0M | $70.5M | $86.7M | $147.9M | $155.3M | $160.6M |
| Generales y Administrativos | $1.3M | $3.2M | $13.9M | $29.8M | $43.4M | $50.2M | $52.3M |
| Gastos Operativos | $2.2M | $3.2M | $84.5M | $116.5M | $204.8M | $205.4M | $205.7M |
| Beneficio Operativo | -$2.2M | -$932000 | -$84.5M | -$116.5M | -$204.8M | -$202.5M | -$208.3M |
| EBITDA | -$2.2M | -$889000 | -$165.3M | -$120.5M | -$186.6M | -$189.8M | -$195.8M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$2.5M | -$1.5M | -$165.9M | -$122.8M | -$198.4M | -$195.9M | -$201.1M |
| Impuestos | $4000 | $1.9M | -$486000 | -$948000 | -$279000 | 0 | 0 |
| Beneficio Neto | -$2.5M | -$3.4M | -$165.4M | -$121.8M | -$198.1M | -$195.9M | -$201.1M |
| BPA | $-0.03 | $-0.05 | $-1.92 | $-1.46 | $-2.18 | $-1.65 | $-1.35 |
| BPA Diluido | $-0.03 | $-0.05 | $-1.92 | $-1.46 | $-2.18 | $-1.65 | $-1.35 |
| Acciones en Circulación (Diluidas) | $95.7M | $95.7M | $95.7M | $97.2M | $91.0M | $118.6M | $148.8M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | $1.2M | $838000 | $856000 | $1.2M |
| Beneficio Bruto | -$42.8M | $838000 | -$1.0M | $1.2M |
| Beneficio Operativo | -$54.0M | -$48.6M | -$50.7M | -$43.3M |
| EBITDA | -$48.7M | -$44.2M | -$47.3M | -$40.3M |
| Beneficio Neto | -$50.6M | -$46.1M | -$49.1M | -$42.1M |
| BPA | $-0.32 | $-0.26 | $-0.28 | $-0.24 |
| BPA Diluido | $-0.32 | $-0.26 | $-0.28 | $-0.24 |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $8.6M | $37.0M | $185.4M | $187.6M | $41.6M | $182.5M | $63.0M |
| Inversiones a Corto | 0 | $16.4M | $84.2M | $106.3M | $80.1M | $8.0M | $114.6M |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $8.7M | $53.4M | $270.6M | $296.6M | $143.0M | $211.9M | $181.3M |
| Inmovilizado Material | 0 | $596000 | $15.7M | $48.6M | $36.6M | $71.6M | $146.7M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $8.7M | $54.8M | $301.9M | $360.3M | $193.9M | $297.5M | $342.7M |
| Cuentas por Pagar | 0 | $250000 | $1.4M | $4.3M | $19.5M | $11.4M | $8.9M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $7.3M | $19.4M | $58.0M | $26.7M | $56.4M | $38.0M | $37.4M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | $108.3M |
| Pasivos Totales | $7.3M | $21.3M | $62.3M | $44.0M | $60.8M | $144.4M | $221.9M |
| Reservas | -$2.6M | -$6.0M | -$171.4M | -$293.2M | -$491.3M | -$687.2M | -$888.4M |
| Patrimonio Neto | $1.4M | $33.5M | $239.6M | $316.3M | $133.1M | $153.1M | $120.9M |
| Deuda Total | 0 | 0 | $10.4M | $28.7M | $13.6M | $40.8M | $116.4M |
| Deuda Neta | -$8.6M | -$53.3M | -$259.2M | -$265.2M | -$108.0M | -$149.6M | -$61.3M |
| Capital Circulante | $1.4M | $34.0M | $212.6M | $269.9M | $86.6M | $173.9M | $143.8M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $71.4M | $63.0M | $64.1M | $47.5M |
| Activos Totales | $385.0M | $342.7M | $294.7M | $249.0M |
| Pasivos Totales | $223.2M | $221.9M | $218.0M | $209.2M |
| Patrimonio Neto | $161.8M | $120.9M | $76.7M | $39.8M |
| Deuda Total | $118.1M | $116.4M | $114.5M | $112.5M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$2.5M | -$3.4M | -$165.4M | -$121.8M | -$198.1M | -$195.9M | -$201.1M |
| Amortizaciones | 0 | $43000 | $568000 | $2.2M | $4.7M | $6.1M | $5.4M |
| Compensación en Acciones | 0 | $391000 | $1.7M | $6.5M | $13.9M | $26.1M | $29.3M |
| Cambio en Capital Circulante | $492000 | $164000 | $31.2M | -$35.4M | $2.6M | $31.1M | -$5.3M |
| Flujo de Caja Operativo | -$1.3M | -$5.5M | -$34.1M | -$131.8M | -$165.4M | -$122.9M | -$162.6M |
| Inversiones (CapEx) | 0 | -$639000 | -$4.2M | -$16.1M | -$8.7M | -$7.3M | -$4.5M |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$1.3M | -$6.2M | -$38.2M | -$147.9M | -$174.1M | -$130.2M | -$167.1M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$35.0M | -$37.3M | -$42.7M | -$41.0M |
| Inversiones (CapEx) | -$247000 | -$290000 | -$214000 | -$46000 |
| Flujo de Caja Libre | -$35.3M | -$37.5M | -$42.9M | -$41.1M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $12.7M | $4.5M | $4.6M | $4.9M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | | -100.0% | | | | +55.3% |
| Crecimiento Beneficio Neto (anual) | | -34.8% | -4749.5% | +26.3% | -62.6% | +1.1% | -2.7% |
| Crecimiento BPA (anual) | | -80.8% | -3542.6% | +24.0% | -49.1% | +24.2% | +18.3% |
| Cambio en Acciones (anual) | | +0.0% | +0.0% | +1.5% | -6.4% | +30.4% | +25.4% |
| Crecimiento FCF (anual) | | -363.5% | -518.3% | -286.9% | -17.7% | +25.3% | -28.4% |
| Margen Bruto | | 42.8% | | | | 100.0% | -58.1% |
| Margen Operativo | | -17.9% | | | | -6787.4% | -4498.1% |
| Margen EBITDA | | -17.1% | | | | -6361.2% | -4226.2% |
| Margen Neto | | -65.5% | | | | -6566.6% | -4342.4% |
| Margen FCF | | -118.7% | | | | -4363.4% | -3607.4% |
| Tasa Impositiva Efectiva | -0.2% | -121.0% | 0.3% | 0.8% | 0.1% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.01 | $-0.06 | $-0.40 | $-1.52 | $-1.91 | $-1.10 | $-1.12 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $95.7M | $95.7M | $95.7M | $97.2M | $91.0M | $118.6M | $148.8M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -188.27% |
| Rentabilidad sobre capital invertido | -86.83% |
| Rentabilidad sobre activos | -75.45% |
| Margen bruto | -1025.61% |
| Margen operativo | -4824.94% |
| Margen neto | -4613.11% |
Salud financiera
| Deuda / Patrimonio | 2.83 |
| Ratio corriente | 3.05 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -3.72 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -526.37 | -291.10 | -7.99 | -12.72 | -4.07 | -1.77 | -2.57 |
| P/VC | 1059.30 | 43.96 | 6.14 | 5.71 | 6.06 | 2.26 | 4.27 |
| P/V | 0.00 | 282.41 | 0.00 | 0.00 | 0.00 | 116.10 | 111.44 |
| Margen Bruto | 0.0% | 42.8% | 0.0% | 0.0% | 0.0% | 100.0% | -58.1% |
| Margen Operativo | 0.0% | -17.9% | 0.0% | 0.0% | 0.0% | -6787.4% | -4498.1% |
| Margen Neto | 0.0% | -65.5% | 0.0% | 0.0% | 0.0% | -6566.6% | -4342.4% |